שולי רווח נקי ממכירות preludetx.com (PRLD)

לוגו גרפי של Prelude (PRLD)

The success of Prelude Therapeutics (PRLD) is based on the precision of targeted inhibitors and the safety of therapy in early tests. Net profit margins illustrate the dynamics of these processes, where the current level is -247.10. Simultaneously, the company is implementing green chemistry principles for environmental sustainability. The absence of commercial revenue makes the business dependent on venture capital investments, which precludes the existence of pricing power.

Prelude Therapeutics Incorporated (PRLD) - שולי רווח נקי מ-04.07.2022 עד 19.11.2026

פילוחים אנליטיים של חברת Prelude Therapeutics Incorporated (PRLD)

- שווי שוק ותחזית יעד של אנליסטים:
אנליטיקה מסכמת של החברה:Prelude Therapeutics Inc. - PRLD
מוצר המיוצר על ידי preludetx.com

To minimize fundamental risks, investors select assets with predictable cash flows. This indicator calculates the ratio of net income to revenue, measuring the efficiency of converting sales into bottom-line profit. For Prelude Therapeutics (PRLD), which develops targeted oncology drugs, this metric reflects the cost of R&D relative to commercialization. Analysis via a balanced net margin allows for an assessment of the biotech's financial stability.